54.41 F
London
April 19, 2025
PI Global Investments
Private Equity

Immunome Issues Private Equity Shares to Ayala


Immunome (IMNM) has released an update to notify the public and investors about the unregistered sales of equity securities.

Shares will be issued to Ayala at the Closing, utilizing an exemption from registration requirements under Section 4(a)(2) of the Securities Act, which applies to private transactions by an issuer. As a result, these shares won’t be publicly registered and can’t be sold in the U.S. without proper registration or a relevant exemption.

For further insights into IMNM stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.



Source link

Related posts

Pan-African private equity firm Admaius strikes fourth bet from first outing

D.William

The problem with private equity’s role in medicine

D.William

PE-backed MKC Wealth snaps up two advice firms

D.William

Leave a Comment

* By using this form you agree with the storage and handling of your data by this website.